Jazz Pharmaceuticals plc
JAZZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $8 | $6 | $8 | $7 |
| - Cash | $1 | $1 | $2 | $2 |
| + Debt | $1 | $5 | $5 | $6 |
| Enterprise Value | $8 | $11 | $11 | $11 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 7.7% | 16.5% | -17.5% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 77.1% | 88.9% | 88.3% | 88.2% |
| EBITDA | $0 | -$1 | $0 | $0 |
| % Margin | 20.9% | -49.2% | 15.5% | 36.5% |
| Net Income | $0 | -$1 | -$0 | $0 |
| % Margin | 22.3% | -68.7% | -10.3% | 17.6% |
| EPS Diluted | 4.08 | -11.74 | -1.52 | 3.11 |
| % Growth | 134.8% | -672.4% | -148.9% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |